The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.